ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details

On Wednesday,

ImmunityBio, Inc.

(NASDAQ:
IBRX
) released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer (NMIBC) and non-small
cell lung cancer (NSCLC)
.

Price Action:

IBRX stock is up 18.6% at $2.835 at last check Thursday.

Read Next:

Photo via Shutterstock.

UNLOCKED: 5 NEW TRADES EVERY WEEK.
Click now to get top trade ideas daily
, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Get the latest stock analysis from Benzinga?

This article
ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details
originally appeared on
Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.